Work

End points for clinical allograft trials; GRFS should not be abandoned

Year: 2026

Type: article

Abstract: Kelkar et al 1 questioned whether "Is it time to move beyond graft-versus-host disease-free, relapsefree survival as a primary end point in clinical trials for hematopoietic cell transplantation?"The answer is not simple and deserves reflection.End points for clinical trials of allogeneic transplantation can vary.Survival, disease-free survival, relapse (for malignancies), and nonrelapse mortality have all been used to capture the complexities of allografting.The preferred end point might best reflect a meaningful clinical milestone for the patients involved and capture the most important elements of transplantation success.

Source: Blood Advances

DOI: 10.1182/bloodadvances.2026021455

Authors: Daniel Weisdorf, Margaret MacMillan, Regis Peffault de la Tour, Jeffrey Miller, Mark Juckett, Gerard Socie

Institutions: University of Minnesota, Hôpital Saint-Louis

Language: English

Topic: Hematopoietic Stem Cell Transplantation

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,800